Marker Therapeutics to Present at Three Upcoming Healthcare Conferences

Houston, Texas – November 08, 2018 – Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate in three upcoming healthcare conferences. Mr. Hoang will participate in a panel discussion titled “Drug Pricing and Development Challenges” at the CEO Life Sciences and Pharmaceuticals Symposium…

Details

The Art of the Question

If you don’t ask the right questions… I long thought writing and journalism were about fact-finding and observation. You had to live the story, to have an interesting life, and as a result, great writing would just happen. If I chased the story, the story would just pour out of me. I’m here to tell…

Details

Marker to Present at Two Upcoming Cellular Therapy Conferences

Houston, Texas – Octerber 18, 2018 – Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming cellular therapy conferences.  Mr. Hoang will present a talk titled, “Moving Beyond CAR-T: Non-Engineered Multi-Antigen Specific T Cells Can Drive Significant Therapeutic Benefit for…

Details

TapImmune’s HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

Mayo Clinic Receives $11 Million to Study TPIV110 in Combination with Trastuzumab (Herceptin®) Jacksonville FL, October 10, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, congratulates Mayo Clinic for being awarded a grant of $11 million from the U.S. Department of Defense (DoD). This grant will cover the costs of a large Phase…

Details

TapImmune To Present at 2018 Janney Healthcare Conference

JACKSONVILLE, Florida – September 12, 2018 – TapImmune Inc . (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will present at the 2018 Janney Montgomery Scott Healthcare Conference being held September 17-18, 2018, at the Union League Club in New York City. He will also be available…

Details

TapImmune to Participate at Two Upcoming Industry Conferences

JACKSONVILLE, Florida – August 29, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming industry conferences.  Mr. Hoang will present and participate in a panel discussion at the Hanson Wade CAR-TCR Summit , to be held September 4-7, 2018,…

Details

FISION and Continuity Logic Announce Entry into Merger Agreement, Creating a First of its Kind Cloud Platform for Critical Business Processes, from Digital Asset Management and Agile Marketing, to Business Continuity and Risk Management

FISION and Continuity Logic Announce Entry into Merger Agreement, Creating a First of its Kind Cloud Platform for Critical Business Processes, from Digital Asset Management and Agile Marketing, to Business Continuity and Risk Management Read: FISION and Continuity Logic Announce Entry into Merger Agreement, Creating a First of its Kind Cloud Platform for Critical Business…

Details